A different pattern of cytotoxic T lymphocyte recognition against primary and metastatic tumor cells in a patient with nonsmall cell lung carcinoma

Cancer

Volumn 103, Issue 1, 2005, Pages 200-208

  So, Tetsuya ^a   Takenoyama, Mitsuhiro ^a   Ichiki, Yoshinobu ^a   Mizukami, Makiko ^a   So, Tomoko ^a   Hanagiri, Takeshi ^a   Sugio, Kenji ^a   Yasumoto, Kosei ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

Cytotoxic T lymphocyte; Immunologic surveillance; Immunotherapy; Nonsmall cell lung carcinoma; Tumor antigen; Tumor escape mechanism

Indexed keywords

B7 ANTIGEN; FAS LIGAND; GAMMA INTERFERON; HLA ANTIGEN CLASS 1; INTERCELLULAR ADHESION MOLECULE 1; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3; RECOMBINANT INTERLEUKIN 2; TUMOR ANTIGEN;

ANIMAL MODEL; ANTIGEN RECOGNITION; ARTICLE; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; LUNG CANCER; LUNG NON SMALL CELL CANCER; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL;

AGED; ANTIBODY FORMATION; ANTIGENS, NEOPLASM; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE PROGRESSION; FLOW CYTOMETRY; HUMANS; IMMUNOTHERAPY; LUNG NEOPLASMS; MALE; NEOPLASM METASTASIS; T-LYMPHOCYTES, CYTOTOXIC; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 10844227451     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.20782     Document Type: Article

References (45)

1. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics. CA Cancer J Clin. 1998;48:6-29.
2. Osaki T, Oyama T, Gu CD, et al. Prognostic impact of micrometastatic tumor cells in the lymph nodes and bone marrow of patients with completely resected Stage I non-small-cell lung cancer. J Clin Oncol. 2002;20:2930-2936.
3. Arriagada R, Bergman B, Dunant A, Le Chevalier T, Pignon JP, Vansteenkiste J. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. International Adjuvant Lung Cancer Trial Collaborative Group. N Engl J Med. 2004;350:351-360.
4. Scagliotti GV, Fossati R, Torri V, et al. Randomized study of adjuvant chemotherapy for completely resected Stage I, II, or IIIA non-small-cell lung cancer. Adjuvant Lung Project Italy/European Organisation for Research and Treatment of Cancer-Lung Cancer Cooperative Group Investigators. J Natl Cancer Inst. 2003;95:1453-1461.
5. Breathnach OS, Freidlin B, Conley B, et al. Twenty-two years of Phase III trials for patients with advanced non-small-cell lung cancer: sobering results. J Clin Oncol. 2001;19:1734-1742.
6. Bremnes RM, Veve R, Hirsch FR, Franklin WA. The E-cadherin cell-cell adhesion complex and lung cancer invasion, metastasis, and prognosis. Lung Cancer. 2002;36:115-124.
7. Curran S, Murray GI. Matrix metalloproteinases: molecular aspects of their roles in tumour invasion and metastasis. Eur J Cancer. 2000;36:1621-1630.
8. Wimmel A, Schilli M, Kaiser U, et al. Preferential histiotypic expression of CD44-isoforms in human lung cancer. Lung Cancer. 1997;16:151-172.
9. Imoto H, Osaki T, Taga S, Ohgami A, Ichiyoshi Y, Yasumoto K. Vascular endothelial growth factor expression in non-small-cell lung cancer: prognostic significance in squamous cell carcinoma. J Thorac Cardiovasc Surg. 1998;115:1007-1014.
10. Yano S, Nishioka Y, Goto H, Sone S. Molecular mechanisms of angiogenesis in non-small cell lung cancer, and therapeutics targeting related molecules. Cancer Sci. 2003;94:479-485.
11. Yasuda M, Tanaka Y, Tamura M, et al. Stimulation of β1 integrin down-regulates ICAM-1 expression and ICAM-1-dependent adhesion of lung cancer cells through focal adhesion kinase. Cancer Res. 2001;61:2022-2030.
12. Yasuda M, Tanaka Y, Fujii K, Yasumoto K. CD44 stimulation down-regulates Fas expression and Fas-mediated apoptosis of lung cancer cells. Int Immunol. 2001;13:1309-1319.
13. Van der Bruggen P, Traversari C, Chomez P, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science. 1991;254:1643-1647.
14. Van den Eynde BJ, Van der Bruggen P. T cell defined tumor antigens. Curr Opin Immunol. 1997;9:684-693.
15. Odunsi K, Jungbluth AA, Stockert E, et al. NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer. Cancer Res. 2003;63:6076-6083.
16. Godelaine D, Carrasco J, Lucas S, et al. Polyclonal CTL responses observed in melanoma patients vaccinated with dendritic cells pulsed with a MAGE-3.A1 peptide. J Immunol. 2003;171:4893-4897.
17. Valmori D, Dutoit V, Ayyoub M, et al. Simultaneous CD8+ T cell responses to multiple tumor antigen epitopes in a multipeptide melanoma vaccine. Cancer Immun. 2003;3:15.
18. Karanikas V, Lurquin C, Colau D, et al. Monoclonal anti-MAGE-3 CTL responses in melanoma patients displaying tumor regression after vaccination with a recombinant canary pox virus. J Immunol. 2003;171:4898-4904.
19. Yutoku M, Fuji H, Grossberg AL, Pressman D. An experimental model for evaluation of factors in tumor escape from immunological attack. Cancer Res. 1975;35:734-739.
20. Khong HT, Restifo NP. Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat Immunol. 2002;3:999-1005.
21. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002;3:991-998.
22. Jennifer RG, Dewayne MF, Mona FM, William EG, Stephanie DD, Penelope AM. Human leukocyte antigen class I allelic and haplotype loss in squamous cell carcinoma of the head and neck: clinical and immunogenetic consequences. Clin Cancer Res. 2000;6:2794-2802.
23. Kurnick JT, Ramirez-Montagut T, Boyle LA, et al. A novel autocrine pathway of tumor escape from immune recognition: melanoma cell lines produce a soluble protein that diminishes expression of the gene encoding the melanocyte lineage melan-A/MART-1 antigen through down-modulation of its promoter. J Immunol. 2001;167:1204-1211.
24. Cefai D, Favre L, Wattendorf E, Marti A, Jaggi R, Gimmi CD. Role of Fas ligand expression in promoting escape from immune rejection in a spontaneous tumor model. Int J Cancer. 2001;91:529-537.
25. Chen W, Frank ME, Jin W, Wahl SM. TGF-β released by apoptotic T cells contributes to an immunosuppressive milieu. Immunity. 2001;6:715-725.
26. Sugaya M, Takenoyama M, Osaki T, et al. Establishment of 15 cancer cell lines from patients with lung cancer and the potential tools for immunotherapy. Chest. 2002;122:282-288.
27. Yasumoto K, Takeo S, Yano T, et al. Role of tumor-infiltrating lymphocytes in the host defense mechanism against lung cancer. J Surg Oncol. 1988;38:221-226.
28. Takenoyama M, Yoshino I, Fujie H, et al. Autologous tumor-specific cytotoxic T lymphocytes in a patient with lung adenocarcinoma: implications of the shared antigens expressed in HLA-A24 lung cancer cells. Jpn J Cancer Res. 1998;89:60-66.
29. Mountain CF, Dresler CM. Regional lymph node classification for lung cancer staging. Chest. 1997;111:1718-1723.
30. Takenoyama M, Yoshino I, Eifuku R, et al. Successful induction of tumor-specific cytotoxic T lymphocytes from patients with non-small cell lung cancer using CD80-transfected autologous tumor cells. Jpn J Cancer Res. 2001;92:309-315.
31. So T, Takenoyama M, Sugaya M, et al. Generation of autologous tumor-specific T cell clones from a patient with adenosquamous carcinoma of the lung. Jpn J Clin Oncol. 2001;31:311-317.
32. Takenoyama M, Yasumoto K, Harada M, et al. Expression of activation-related molecules on regional lymph node lymphocytes in human lung cancer. Immunobiology. 1996;195:140-151.
33. Takenoyama M, Yasumoto K, Harada M, Sugimachi K, Nomoto K. Antitumor response of regional lymph node lymphocytes in human lung cancer. Cancer Immunol Immunother. 1998;47:213-220.
34. Garrido F, Cabrera T, Concha A, Glew S, Ruiz-Cabello F, Stern PL. Natural history of HLA expression during tumor development. Immunol Today. 1993;14:491-499.
35. Diederichsen AC, Stenholm AC, Kronborg O, et al. Flow cytometric investigation of immune-response-related surface molecules on human colorectal cancers. Int J Cancer. 1998;79:283-287.
36. + CTL. J Immunol. 2000;164:4941-4954.
37. Hahne M, Rimoldi D, Schroter M, et al. Melanoma cell expression of Fas (Apo-1/CD95) ligand: implications for tumor immune escape. Science. 1996;274:1363-1366.
38. O'Connell J, O'Sullivan GC, Collins JK, Shanahan F. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med. 1996;184:1075-1082.
39. Niehans GA, Brunner T, Frizelle SP, et al. Human lung carcinomas express Fas ligand. Cancer Res. 1997;57:1007-1012.
40. Gaugler B, Van den Eynde B, Van der Bruggen P, et al. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J Exp Med. 1994;179:921-930.
41. Yoshimatsu T, Yoshino I, Ohgami A, et al. Expression of the melanoma antigen-encoding gene in human lung cancer. J Surg Oncol. 1998;67:126-129.
42. Jang SJ, Soria JC, Wang L, et al. Activation of melanoma antigen tumor antigens occurs early in lung carcinogenesis. Cancer Res. 2001;61:7959-7963.
43. Hirohashi Y, Torigoe T, Maeda A, et al. An HLA-A24-restricted cytotoxic T lymphocyte epitope of a tumor-associated protein, survivin. Clin Cancer Res. 2002;8:1731-1739.
44. Selvaggi G, Scagliotti GV, Torri V, et al. HER-2/neu overexpression in patients with radically resected nonsmall cell lung carcinoma. Impact on long-term survival. Cancer. 2002;94:2669-2674.
45. Kikuchi T, Daigo Y, Tsunoda T, et al. Expression profiles of non-small cell lung cancers on cDNA microarrays: identification of genes for prediction of lymph-node metastasis and sensitivity to anti-cancer drugs. Oncogene. 2003;22:2192-2205.